【肝病】丙型肝炎直接抗病毒药物临床试验评价专家建议.pdf

Öлª¸ÎÔಡÔÓÖ¾2016Äê3ÔµÚ24¾íµÚ3ÆÚChinJHepatol£¬March2016£¬V01£®24£¬No£®3 ¡¤×¨¼Ò÷롤 ±ûÐ͸ÎÑ×Ö±½Ó¿¹²¡¶¾Ò©ÎïÁÙ´²ÊÔÑéÆÀ¼Ûר¼Ò½¨Òé ¹ú¼Ò¡°ÖØ´óÐÂÒ©´´ÖÆ¡±¿Æ¼¼ÖØ´óרÏî¡°ÖØ´ó¼²²¡ÐÂÒ©ÁÙÀ´ÆÀ¼ÛÑо¿×ۺϼ¼Êõƽ̨½¨É衱¿ÎÌâϸ ͨÐÅ×÷Õߣº·¶Ñ§¹¤£¬Email£ºxgfan57@126£®com£¬410008³¤É³£¬ÖÐÄÏ´óѧÏæÑÅÒ½Ôº¸ÐȾ²¡¿Æ DOI£º10£®370Ycnnj¡£iss¡¾L100¡Þ418£®2016£®03£®001 ¡¾¹Ø¼ü´Ê¡¿¸ÎÑײ¡¶¾£¬±ûÐÍ£» Ö±½Ó¿¹²¡¶¾Ò©Î ÁÙ´²ÊÔÑé »ù½ðÏîÄ¿£º¹ú¼ÒÖØ´ó¿Æ¼¼×¨Ïî(2012ZX09303014) Expertadvicesfor evaluating clinicaltrialsofdirect-actingantJviròÄagentsforhepatitisCResearch Groupfor NewDrug'sClinicalEvalutaionofCriticalDiseasesandPlatformConstructionofIntegratedTechnology Corresponding author£ºFan Xuegong,Email£ºxgfan57@126£®com£¬XiangyaHospital,Central South University, Changsha41000&China [Keywords]Hepatitis C virus£»Direct-acting antiviral agents£»Clinical trial Fund program£ºNational Scienceand TechnologyMajorProjects(2012ZX09303014) ½üÄêÀ´£¬±ûÐ͸ÎÑ×Ö±½Ó¿¹²¡¶¾Ò©Îï(direct-acting antiviralagents£¬DAA)µÄÑо¿¿ª·¢ÒѽøÈë¿ìËÙ·¢ Õ¹½×¶Î£¬²»¶ÏÓÐÐÂÒ©»ñ×¼ÉÏÊС£DAAµÄ³öÏÖ¶ÔÓÚ ±ûÐ͸ÎÑ×µÄÖÎÁƾßÓл®Ê±´úµÄÒâÒ壬Ëü²»½öÌá¸ß Á˱ûÐ͸ÎÑ×µÄÖÎÁÆЧ¹û£¬»¹ÓпÉÄÜÈ¡´ú¸ÉÈÅËؽö (interferon-alpha£¬IFN0¡¾)£¬³ÉΪһÖÖеıê×¼ÖÎÁÆ¡£ Ä¿Ç°¹úÄÚÒÑÓÐÔ½À´Ô½¶àµÄÁÙ´²Ò½Ê¦ºÍÒ½ÁƵ¥Î»ÔÚ²» ͬ³Ì¶ÈÉϲÎÓëDAAµÄÒ©ÎïÁÙ´²ÊÔÑ鹤×÷£¬µ«¹úÄÚÉÐ ÎÞÏà¹ØÖ¸ÄÏ»ò¹æ·¶£¬ÎªÊ¹Õâ·½ÃæµÄ¹¤×÷¸ü¹æ·¶¡¢¸ü ·ûºÏ¹úÄÚÐÂÒ©ÆÀ¼ÛµÄÒªÇó²¢Óë¹ú¼Ê½Ó¹ì£¬ÎÒÃÇ×éÖ¯ Á˹úÄÚ²¿·ÖÖªÃûר¼Ò£¬¾Í±ûÐ͸ÎÑ×DAAµÄÐÂÒ©ÁÙ´² ÊÔÑéµÄÏà¹ØÎÊÌâ½øÐÐÁ˹㷺ÌÖÂÛ£¬²¢²Î¿¼¹úÄÚÍâÏà ¹ØÎÄÏ×£¬ÐγÉÁË¡¶±ûÐ͸ÎÑ×Ö±½Ó¿¹²¡¶¾Ò©ÎïÁÙ´²ÊÔ ÑéÆÀ¼Ûר¼Ò½¨Òé¡·(ÒÔϼò³Æ((½¨Òé¡·)¡£ ±¾¡¶½¨Òé))ÊÇ»ùÓÚÄ¿Ç°ÂýÐÔ±ûÐ͸ÎÑ׿¹²¡¶¾(HCV) ÖÎÁƵÄ×îгɹû£¬×ñÕÕѭ֤ҽѧµÄÔ­Ôò±àд£¬Ö÷ÒªÕë ¶ÔII¡¢IIIÆÚÒ©ÎïÁÙ´²ÊÔÑ飬Ëæ×ÅÏà¹ØÁÙ´²Ö¤¾ÝµÄ²»¶Ï »ýÀÛ£¬×¨¼ÒίԱ»á½«¶Ô¡¶½¨Òé¡·ÄÚÈݽøÐиüС£ DAAÓÖ³ÆHCVÌØÒìÐÔ°ÐÏò¿¹²¡¶¾ÖÎÁÆÒ©ÎÕâ ЩҩÎïÌØÒìÐÔ×÷ÓÃÓÚHCV¸´ÖÆÖÜÆÚ¡£¸ù¾ÝÒ©Îï×÷ Óò¿Î»£¬¿É·ÖΪNS3£¯4Aµ°°×øÒÖÖƼÁ¡¢NS5Aµ°°× øÒÖÖƼÁ¡¢ºËÜÕÀàÓë·ÇºËÜÕÀàNS5Bµ°°×øÒÖÖƼÁ ÓëÄÚ²¿ºËÌÇÌå½øÈëλµã(intemal ribosome entrysite£¬ IRES)ÒÖÖƼÁµÈ¡£ Ò»¡¢²¡ÀýÑ¡Ôñ(ÊÜÊÔÕßÌØÕ÷¼°Ñ¡Ôñ) 1£®ÂýÐÔ±ûÐ͸ÎÑ׵Ķ¨ÒåºÍÕï¶Ï±ê×¼£ºH